Infigratinib (BGJ398): an investigational agent for the treatment of FGFR-altered intrahepatic cholangiocarcinoma
Expert Opinion on Investigational Drugs | December 12, 2020 | Volume: 30 | Issue: 4 | Pages: 309-316
10.1080/13543784.2021.1864320
| PMID 33307867